Last updated on October 2017

Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin in Unresectable Peripheral Lung Cancer


Brief description of study

This research study is being conducted to assess the safety and feasibility of using a new developed bronchoscopic technology called electronavigational bronchoscopy to treat subjects with solid tumor in peripheral lung, who are inoperable or refused surgery, and are not candidates or refused radiation therapy. It will involve 10 sites in USA and Canada. Participation will last 6 months.

Detailed Study Description

Lung cancer accounts for almost one-third of cancer deaths. Cancer screening strategies have the potential to achieve a 20% reduction in death rates. Newly developed bronchoscopic technologies (such as navigational bronchoscopy) have shown to enable physicians to safely reach lesions in peripheral regions of the lung and obtain diagnosis. This new technology may now potentially offer bronchoscopic therapeutic interventions, such as photodynamic therapy, to tumors that were previously unreachable due to their peripheral anatomic location. Photodynamic therapy (PDT) uses a combination of a photosensitizing drug (a drug that is activated by light), called porfimer sodium (Photofrin®), and a light from a laser that emits no heat. This technique works to allow the medical doctor to specifically target and destroy abnormal or cancer cells while limiting damage to surrounding healthy tissue. The activation of the drug is done by lighting the abnormal area using a fiber optic device (very fine fiber [like a fishing line] that permits light transmission) inserted into a flexible tube called bronchoscope. The light activates the porfimer sodium, which is concentrated in the abnormal tissue, leading to its destruction. The purpose of this study is to determine if physicians can reach the tumors in the periphery of the lung via electronavigational bronchoscopy and deliver the photodynamic therapy by placing the optical fiber into the tumor.

Clinical Study Identifier: NCT02916745

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Benjamin Wei, MD

The University of Alabama at Birmingham
Birmingham, AL United States
  Connect »

Hiren Mehta, MD

University of Florida
Gainesville, FL United States
  Connect »

Rabih Bechara, MD

Southeastern Regional Medical Center
Atlanta, GA United States
  Connect »

Gaetane Michaud, MD

New York University
New York, NY United States
  Connect »

Daniel A Nader, DO

Southwestern Regional Medical Center
Tulsa, OK United States
  Connect »

John S Ferguson, MD

University of Wisconsin-Madison
Madison, WI United States
  Connect »

Kazuhiro Yasufuku, MD

Toronto General Hospital
Toronto, ON Canada
  Connect »